Clinical Trials Logo

Toxicity Due to Chemotherapy clinical trials

View clinical trials related to Toxicity Due to Chemotherapy.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04737265 Active, not recruiting - Breast Cancer Clinical Trials

Pilot Study of an NTproBNP Guided Strategy of Cardioprotection

NTproBNP-Guide
Start date: March 18, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Investigators will evaluate the safety and feasibility of a biomarker-guided cardioprotection strategy using NTproBNP, as compared to usual care, in breast cancer and lymphoma patients treated with anthracyclines.

NCT ID: NCT04023110 Active, not recruiting - Breast Cancer Clinical Trials

Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab

CCTGuide Pilot
Start date: August 9, 2019
Phase: Phase 1
Study type: Interventional

Investigators will evaluate the safety, tolerability, and feasibility of a risk-guided cardioprotective treatment strategy with carvedilol, as compared to usual care, in breast cancer patients undergoing treatment with doxorubicin, trastuzumab, or the combination.

NCT ID: NCT02856048 Active, not recruiting - Cancer Clinical Trials

Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer

PRESOV
Start date: November 23, 2016
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy of a temporary ovarian suppression obtained by administration of a gonadotropin releasing hormone agonist during alkylating agents containing chemotherapy on ovarian reserve assessed by Anti-Müllerian hormone (AMH) serum levels in adolescents and young women with cancer.